SYMBOL:

    Up to 100 tickers separated by a space .....Watch Post-Market activities
Site Map FAQ Contact us Home Personalize
Company
Industry
Earnings
US Markets
Most Active
Portfolio
Tools
ETFs
Ratings
CYTOKINETICS
(NQSC:CYTK Last Sale: 15.17 +0)
Fundamentals Charts Tech Analysis Industry Earnings
Company Profile   Details

Company Web Site
NQSC: (CYTK : $15.17)
$901,991 million Market Cap at Market Close, July 1, 2022
Biomedics SubIndustry up .00% / Health Industry up .00% Today
280 East Grand Avenue Research Report Earnings Snapshot - Last 10/30/18
South San Francisco, CA 94080 Fact Sheet
Phone: (650) 624-3000 Financial Statements
Peer Comparison
Annual Reports

James H. Sabry, Co-Founder/CEO, Robert I. Blum, Pres., Sharon A. Surrey-Barbari CFO
Work centers on the cytoskeleton, and the cell proliferation process. looking for potentially safer and more effective classes of drugs directed at treatments for cancer, cardiovascular disease, fungal diseases and other diseases. Drug candidate, SB-715992, is in a Phase II clinical trials program designed to evaluate its effectiveness in different types of cancer. Founded in 1997. Credit Suisse Group holds 15.9%, Paul Allen's Vulcan Ventures has 11.9%, and GlaxoSmithKline has 7.7%. IPO at $13 April 28, 2004. Raised $89.7 million, selling 6.9 million shares, 27% of the outstanding. Lead Manager: Goldman Sachs.
Historical Charts    Technical Analysis
No Historical Data available for CYTK

Type of Stock Symbol Last Sale Last Close Net +/- % +/- Low High Volume 52wk Low 52wk High Shares(M)
Common CYTK $15.17 $15.17 0 .0 $14.11 $15.22 562,895 $14.11 $15.22 59,458,852
Capitalization
Earnings Summary ()
*** No Earnings Available***
-10121
Common Stock $901,990,785

A
Google



QUICK NAVIGATION SITE SEARCH   Enter Keyword:
   
Home    Subscribe    Browser Help    Subscriber Services    B-to-B    Banks    Brokerage    Telco    Site Map    Legal    Contact/Email
Copyright © 1996 - 2024 Stock Smart with all rights reserved
Feed is currently being brought back up
Provided by Nanex